Imagine reducing the time to identify a drug that shows results in the clinic to five years: this proof-of-concept study shows it is possible now

The study identifies the first clinical candidate developed using HUB Organoids® and high-content screening that inhibits tumor growth and metastasis in colorectal cancer.